Asymmetrische elektrophile α-Amidoalkylierung, 8. Mitt.: Gewinnung optisch aktiver α-Phenacylpyrrolidinamide und erste asymmetrische Totalsynthese des Norruspolins

Asymmetric Electrophilic α-Amidoalkylation, VIII¹): Syntheses of Optically Active α-Phenacylpyrrolidinamides and First Asymmetric Total Synthesis of Norruspoline The α-phenacyl pyrrolidinamides (R)- 4 /(S)- 5a-e are prepared stereoselectively by reaction of the chiral non racemic α-methoxyamide 1 with silyl enolethers 2a-d . The geminal bisamides (R)- 12 /(S)- 13 are formed from 1 and the bistrimethylsilyl imidate 11 . (R)- 4d is employed in the synthesis of optically active norruspoline (R)- 16 (ee ≧ 84%).     

Lactone, 23. Mitt.: Synthese und Stereochemie „γ-lactonisierter”︁ Neuroleptika vom Butyrophenon-Typ

Lactones, XXIII: Synthesis and Stereochemistry of ?γ-Lactonized”? Butyrophenone-type Neuroleptics ?γ-Lactonized”? neuroleptics ( 1,2a-c ) can be obtained by reaction of α-formyl, α-carboxy- and α-methylene-lactones 5-7a,b with amines 8a - c . 6a, 1a-c were cis/trans-mixtures with predominating cis-compounds, 6b, 2a cis/trans-mixtures with predominating trans-compounds and 2b , c were isolated as pure trans-isomeres.     

An efficient and practical EPC synthesis of β-amino acids from L-asparagine

The synthesis of enantiomerically pure β-arnino acids (1a-c) via an O-activated equivalent of β-homoserine is discussed. The chiral synthon 2 was planned to be represented by (S)-3-N,N-dibenzylamino-4-mesyloxybutanoic acid methyl ester (3) or by (S)-3-N,N-dibenzylamino-4-mesyloxybutanenitrile (6). Both intermediates should be approached from L-aspartic acid 4 or L-asparagine 5 through selective reduction of the α-carboxyl group. It turned out that only nitrile 6 was suitable for the envisioned β-amino acid synthesis, since alcohol 14 - the synthetic precursor of 3 - was unstable towards intramolecular nucleophilic attack to accomplish the chiral building block 15. Reaction of mesylate 6 with different ‘Gilman cuprates’ afforded the 3-N,N-dibenzylamino nitrile derivatives 22a-c, which could be readily deprotected to give the target compounds 1a-c in 23-36% overall yield from asparagine. In contrast Me₂Cu(CN)Li₂ as an example for higher order ‘Lipshutz cuprates’ did not afford the desired substitution product 22a. The optical integrity of the synthesis was established by coupling of the methyl ester 24 with chiral 1-phenylethyl isocyanate followed by appropriate NMR studies of carbamate 25.     

Sukzessive Ringmethylierung von α-Piperidino-oximen durch wiederholte Zwei-Stufen-Reaktion

Successive Ring Methylation of α-Piperidino-oximes by Repetitive Two-Step-Reaction Dehydrogenation of α-piperidino-acetophenonoximes with Hg(II)-edta, followed by Grignard reaction, succeeds in the stepwise ring methylation of the piperidine moiety, both E- and Z-isomers retaining their configurations. The kind of ring connection of the bicyclic products is determined by ¹³C-NMR-data.     

Synthesis of β and γ-fluorenylmethyl esters of respectively Nα-Boc-L-aspartic acid and Nα-Boc-L-glutamic acid

The orthogonal synthesis of N^x-Boc-L-aspartic acid-γ-fluorenylmethyl ester and N^α-Boc-L-glutamic acid-δ-fluorenylmethyl ester is reported. This is a four-step synthesis that relies on the selective esterification of the side-chain carboxyl groups on N^x-CBZ-l -aspartic acid and N^α-CBZ-l -glutamic acid. Such selectivity is accomplished by initially protecting the a-carboxyl group through the formation of the corresponding 5-oxo-4-oxazolidinone ring. Following side-chain esterification, the α-carboxyl and α-amino groups are deprotected with acidolysis. Finally, the α-amino group is reprotected with the t-butyl-oxycarbonyl (Boc) group. Thus aspartic acid and glutamic acid have their side-chain carboxyl groups protected with the base-labile fluorenylmethyl ester (OFm) and their α-amino groups protected with the acid-labile Boc group. These residues, when used in conjunction with N^x-Boc-N^ε-Fmoc-l -lysine, are important in the formation of side-chain to side-chain cyclizations, via an amide bridge, during solid-phase peptide synthesis.     

α-Alkylmercapto- und α-Arylmercapto-alkylisocyanate

α-Alkylmercapto- and α-Arylmercapto-alkylisocyanates α-Alkylmercapto- and α-arylmercapto-alkylisocyanates 2 were prepared from α-halosulfides 1 by reaction with silver cyanate. With ammonia, primary or secondary amines they give the corresponding α-mercaptoalkyl-ureas 4 ; with alcohols, the α-mercaptoalkylurethans 3.     

Pharmacological characterization of A-131701, a novel α1-adrenoceptor antagonist selective for α1A- and α1D-compared to α1B-adrenoceptors

New compounds selective for α_1A-adrenoceptors in the prostate may offer enhanced efficacy for benign prostatic hyperplasia (BPH), with fewer side effects than current treatment. A-131701 (3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b,hexahydro-[1H]-benz[e]isoindol-2-yl)ethyl]pyrido[3′,4′:4,5]thieno [3,2-d]pyrimidine-2,4(1H,3H)-dione), from a novel class of benz[e]isolindole pyridothienopyrimidines and pyridothienopyrazines, is selective for α_1a- and α_1d-adrenoceptors in radioligand binding studies (0.22 nM at α_1a-, 0.97 nM at α_1d-) compared to α_1b-sites (2.5 nM) and in isolated tissue bioassays (pA₂ values of 8.9–9.0 for α_1A-receptors in rat vas deferens or canine prostate strips, 9.1 at α_1D-sites (rat aorta)), compared to 7.9 at α_1B-sites (rat spleen). A-131701 also potently blocked radioligand binding to α₁-adrenoceptors in canine and human prostatic membranes, but was considerably weaker at α₂-adrenoceptors. In isoflurane-anesthetized dogs, A-131701 antagonized epinephrine-induced increases in intraurethral pressure (IUP) with a pseudo-pA₂ value of 8.17. In spontaneously hypertensive rats, A-131701 caused transient decreases in mean arterial blood pressure (MABP) and transient tachycardia. The area under the curve (AUC₀→₆₀ min) for the hypotensive response was dose-related, with a log index value for A-131701 of 5.33, suggesting a selectivity of >600-fold comparing IUP to MABP effects. In pentobarbital-anesthetized dogs, A-131701 was more potent in blocking phenylephrine (PHE)-induced increases in IUP (pseudo-pA₂ = 8.0) compared to concurrently measured MABP (pseudo-pA₂ = 7.2), or sixfold selective. Doses greater than 1,000 nmol/kg i.v. of A-131701 were required to lower blood pressure by 10 mm Hg in these dogs (pED₁₀ =. 5.57), indicating a uroselectivity ratio of >250, superior to doxazosin, terazosin, or tamsulosin. Thus, A-131701 is selective for α_1A- and α_1D- vs. α_1B-adrenoceptors in vitro, and prostatic function vs. blood pressure effects in vivo, which may provide therapeutic advantages in the treatment of BPH. Drug Dev. Res. 44:140–162, 1998. © 1998 Wiley-Liss, Inc.     

In vitro functional evaluation of isolaureline,dicentrine and glaucine enantiomers at 5‐HT2 and α1 receptors

Compounds with activity at serotonin (5‐hydroxytryptamine) 5‐HT₂ and α₁ adrenergic receptors have potential for the treatment of central nervous system disorders, drug addiction or overdose. Isolaureline, dicentrine and glaucine enantiomers were synthesized, and their in vitro functional activities at human 5‐HT₂ and adrenergic α₁ receptor subtypes were evaluated. The enantiomers of isolaureline and dicentrine acted as antagonists at 5‐HT₂ and α₁ receptors with (R)‐isolaureline showing the greatest potency (pK_b = 8.14 at the 5‐HT_2C receptor). Both (R)‐ and (S)‐glaucine also antagonized α₁ receptors, but they behaved very differently to the other compounds at 5‐HT₂ receptors: (S)‐glaucine acted as a partial agonist at all three 5‐HT₂ receptor subtypes, whereas (R)‐glaucine appeared to act as a positive allosteric modulator at the 5‐HT_2A receptor.     

Synthesis of α-, β- and cyclic spaglumic acids

A short, one-pot synthesis of α- and β-spaglumic acids (N-acetyl-L-aspartyl-L-glutamic acids, NAAGA) has been developed based on ultrasound-promoted acetylation of aspartic acid, followed by dehydration, condensation with glutamic acid dibenzyl ester and hydrogenolysis. The α- and β-peptides were separated by anion-exchange chromatography. The α-peptide shows a remarkable tendency to cyclize during methylation with diazomethane and yields cyclic N-acetylaspartylglutamic acid dimethyl ester, which could be hydrolysed to the hitherto unreported diketopiperazine dicarboxylic acid, cyclic spaglumic acid (cyclic NAAGA).     

Synthese von 3-methylenmonosubstituierten 2-Oxo-tetrahydrofuranen durch Umsetzung von α-Keto-γ-lactonen mit Wittig-Reagenzien

Synthesis of 3-Methylenetetrahydrofuran-2-ones from α-Keto-γ-lactones with Wittig Reagents The synthesis of the 3-methylenetetrahydrofuran-2-ones 3a--q from the α-keto-γ-lactones 1a,b and the Wittig compounds 2a--h is described.     

Crystal structures of a nonapeptide helix containing α, α-di-n-butylglycine (Dbg), Boc-G1y-Dbg-Ala-Val-Ala-Leu-Aib-Val-Leu-OMe

Two crystal structures of a nonapeptide (anhydrous and hydrated) containing the amino acid residue α,α-di-n-butylglycyl, reveal a mixed 3₁₀-α-helical conformation. Residues 1-7 adopt φ, ψ values in the helical region, with Val(8) being appreciably distorted. The Dbg residue has φ, ψ values of -40, -37° and -46, -407° in the two crystals with the two butyl side chains mostly extended in each. Peptide molecules in the crystals pack into helical columns. The crystal parameters are: C₅₀ H₉₁ N₉ O₁₂, space group P2₁, with a= 9.789(1)Å;, b= 20.240(2) Å. c= 15.998(3) Å. β= 103.97(1): Z= 2, R=10.3% for 1945 data observed < 3σ(F) and C₅₀H₉₁N₉O₁₂· 3H₂O, space group P2₁ with a= 9.747(3)Å, b= 21.002(8) Å, c= 15.885(6) Å, β= 102.22(3). Z= 2. R=13.6% for 2535 data observed < 3σ(F) The observation of a helical conformation at Dbg suggests that the higher homologs in the α,α-dialkylated glycine series also have a tendency to stabilize peptide helices. © Munksgaard 1996.     

Two peptides released in the complex formation of α1 -antitrypsin with β-trypsin; evidence for two structurally identical,inhibitory sites in α1-antitrypsin

The exact mechanism of action of α₁-antitrypsin, the major protease inhibitor in human serum, is still unknown. Several investigators report the release of a small peptide during complex formation of α₁-antitrypsin with various proteases. In this study the release of two peptides each from the NH₂-and the COOH-terminal regions of α₁ -antitrypsin is demonstrated, indicating the presence of two inhibitory sites in α₁ -antitrypsin. The amino acid sequence near the NH₂ -terminal inhibitory site is determined to be X-Ser-Ile-Pro-Pro- and near the COOH-terminal inhibitory site Y-Ala-Ile-Pro-Met-Ser-Ile-Pro. The combined results of the present report and several other reports indicate the presence of two structurally identical inhibitory sites in α₁-antitrypsin located at both terminal regions in the molecule.     

Synthesis of N-tert.-butoxycarbonyl(α-phenyl)aminomethylphenoxyacetic acid for use as a handle in solid-phase synthesis of peptide α-carboxamides

N-tert.-butoxycarbonyl-aminomethyl(α-phenyl)phenoxyacetic acid was synthesized and found to be suitable for use as a handle in the solid-phase synthesis of peptide α-carboxamides. This handle was prepared with an 82% yield when N-tert.-butoxycarbonyl-(p-hydroxy)benzhydrylamine was treated with excess sodium iodoacetate under alkaline conditions. In stability studies the linkage between the C-terminal amino acid and the handle was found to be resistant to acidolysis in 50% TFA/CH₂Cl₂ (< 1% loss after 10h). Upon treatment for 30min with HF:anisole(9:1) at 0°, 92% cleavage of glycinamide from Glyhandle-resin was obtained. In a test synthesis of a peptide α-carboxamide, pyroglutamylhistidylprolinamide was synthesized in 83% yield. Two other handles, tert.-butoxycarbonyl-aminomethylphenoxyacetic acid and N-tert.-butoxycarbonyl-aminornethylphenyloxymethylphenoxyacetic acid, were also synthesized but found to be unsuitable for carboxamide synthesis under the same conditions of solid-phase synthesis.     

Umlagerung von Δ1-pyrrolinsubstituierten α-Acetylenalkoholen

Rearrangement of α-Acetylenic Alcohols Substituted with Δ¹-Pyrroline α-Acetylenic alcohols substituted with Δ¹-pyrroline are formed by 1,2-addition of 2-alkyl-Δ¹-pyrrolines to propargylic aldehydes. Thermolytic rearrangement of the products leads to vinylogous formamides and Meyer-Schuster products.     

Synthese substituierter 3-Adamantyloxocumarine unter Piperidinacetat/β-Alanin-Katalyse

Synthesis of Substituted 3-Adamantyloxocoumarines in the Presence of Piperidine acetate/β-Alanine The synthesis of the substituted 3-adamantyloxocoumarines 3a-h from the hydroxyaldehydes 1a-h by Knoevenagel reaction with 2 in the presence of piperidine acetate/β-alanine is described.     

The α‐adrenoceptor antagonist,zolertine, inhibits α1D‐ and α1A‐adrenoceptor‐mediated vasoconstriction in vitro

1 The antagonist effect of zolertine (4‐phenyl‐1‐[2‐(5‐tetrazolyl)ethyl]piperazine trihydrochloride), on vascular contraction elicited by noradrenaline in aorta, carotid (α1D‐adrenoceptors), mesenteric (α1A/D‐adrenoceptors) and caudal arteries (α1A‐adrenoceptors) from Wistar Kyoto (WKY) and spontaneously hypertensive (SHR) rats and rabbit aorta (α1B‐adrenoceptors), was investigated in endothelium‐denuded arterial rings.
2 The selective α1D‐adrenoceptor agonist, noradrenaline, elicited concentration‐dependent contractions in all arterial rings from both species. Noradrenaline selectivity was: carotid=aorta>>.Gt;mesenteric=rabbit aorta>caudal arteries.
3 The contractile responses induced by noradrenaline were competitively antagonized by zolertine in rat carotid and aorta arteries, yielding pA2 values of WKY, 7.48±0.18; SHR, 7.43±0.13 and WKY, 7.57±0.24; SHR, 7.40±0.08, respectively. Zolertine was a non‐competitive antagonist in some blood vessels as Schild plot slopes were lower than unity. The pKb estimates for zolertine were WKY, 6.98±0.16; SHR, 6.81±0.18 in the mesenteric artery, WKY, 5.73±0.11; SHR, 5.87±0.25 in the caudal artery and 6.65±0.09 in rabbit aorta.
4 Competition binding experiments using the α1‐adrenoceptor antagonist [³H]prazosin showed a zolertine pKi of 6.81±0.02 in rat liver (α1B‐adrenoceptors) and 6.35±0.04 in rabbit liver (α1A‐adrenoceptors) membranes.
5 Zolertine showed higher affinity for α1D‐adrenoceptors compared to α1A‐adrenoceptors, while it had an intermediate affinity for α1B‐adrenoceptors. The ability of the α1‐adrenoceptor antagonist zolertine to block α1D‐adrenoceptor‐mediated constriction in different vessels of WKY and SHR rats may explain its antihypertensive efficacy despite its low order of potency.     

Massenspektrometrische Untersuchungen an isomeren α,β- und β, γ-ungesättigten Ketonen mit raumerfüllenden Substituenten

A Mass Spectrometric Study on Isomeric α,β- and β,γ-Unsaturated Ketones with Bulky Substituents The mass spectra of the α,β- and β,γ-unsaturated ketones 1-4 (scheme 1) are very different depending on the stereochemistry of the double bond. The E-configurated ketone 2 predominantly shows McLafferty fragmentation, whereas Z-configurated ketone 1 reveals ?-cleavage. In the β, γ-unsaturated ketones 3 and 4, mainly loss of the pertinent allyl radical by α-cleavage was observed.     

Molluskizid wirksame Spiro-α-methylen-γ-butyrolactone

α-Methylene-γ-butyrolactones with Molluscicidal Activity The α-methylene-γ-butyrolactones 1-28 were tested in vitro for molluscicidal activity against Biomphalaria glabrata. The racemic compound 25 shows the best activity. The synthesis was carried out by modified Reformatzky reaction of the corresponding carbonyl compounds and bromomethylacrylic acid ethyl ester. 7-10, 17 and 22-27 have been synthesized for the first time.     

Synthesis of an analogue of α-MSH-(1–10)-decapeptide as a substrate for enzymatic Nα-acetylation

The synthesis of a stable substrate for enzymatic N^α-acetylation is described. To this end an analogue of α-MSH-(1–10)-decapeptide with norleucine instead of methionine at position 4 is prepared. t-Butylation of an intermediate Z-Tyr-OMe leads only to about 75% conversion in a few hours' reaction time, and cannot be carried to completion. The [Nle⁴]-decapeptide is as good a substrate for enzymatic N^α-acetylation as the original decapeptide containing methionine.     

Methadone is a Non‐Competitive Antagonist at the α4β2 and α3* Nicotinic Acetylcholine Receptors and an Agonist at the α7 Nicotinic Acetylcholine Receptor

Nicotine–methadone interactions have been studied in human beings and in various experimental settings regarding addiction, reward and pain. Most methadone maintenance treatment patients are smokers, and methadone administration has been shown to increase cigarette smoking. Previous in vitro studies have shown that methadone is a non‐competitive antagonist at rat α3β4 nicotinic acetylcholine receptors (nAChR) and an agonist at human α7 nAChRs. In this study, we used cell lines expressing human α4β2, α7 and α3* nAChRs to compare the interactions of methadone at the various human nAChRs under the same experimental conditions. A [³H]epibatidine displacement assay was used to determine whether methadone binds to the nicotinic receptors, and ⁸⁶Rb⁺ efflux and changes in intracellular calcium [Ca²⁺]_i were used to assess changes in the functional activity of the receptors. Methadone displaced [³H]epibatidine from nicotinic agonist‐binding sites in SH‐EP1‐hα7 and SH‐SY5Y cells, but not in SH‐EP1‐hα4β2 cells. The K_i values for methadone were 6.3 μM in SH‐EP1‐hα7 cells and 19.4 μM and 1008 μM in SH‐SY5Y cells. Methadone increased [Ca²⁺]_i in all cell lines in a concentration‐dependent manner, and in SH‐EP1‐hα7 cells, the effect was more pronounced than the effect of nicotine treatment. In SH‐EP1‐hα4β2 cells, the effect of methadone was negligible compared to that of nicotine. Methadone pre‐treatment abolished the nicotine‐induced response in [Ca²⁺]_i in all cell lines expressing nAChRs. In SH‐EP1‐hα4β2 and SH‐SY5Y cells, methadone had no effect on the ⁸⁶Rb⁺ efflux, but it antagonized the nicotine‐induced ⁸⁶Rb⁺ ion efflux in a non‐competitive manner. These results suggest that methadone is an agonist at human α7 nAChRs and a non‐competitive antagonist at human α4β2 and α3* nAChRs. This study adds further support to the previous findings that opioids interact with nAChRs, which may underlie their frequent co‐administration in human beings and might be of interest to the field of drug discovery.